Zhu Jian, Han Junfeng, Liu Liehua, Liu Yu, Xu Wen, Li Xiaomu, Yang Lin, Gu Yong, Tang Wei, Shi Yongquan, Ye Shandong, Hua Fei, Xiang Guangda, Liu Ming, Sun Zilin, Su Qing, Li Xiaoying, Li Yuxiu, Li Yanbing, Li Hong, Li Yiming, Yang Tao, Yang Jing, Shi Lixin, Yu Xuefeng, Chen Li, Shao Jiaqing, Liang Jun, Han Xiao, Xue Yaomin, Ma Jianhua, Zhu Dalong, Mu Yiming
Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China.
Diabetes Res Clin Pract. 2023 Mar;197:110568. doi: 10.1016/j.diabres.2023.110568. Epub 2023 Feb 3.
Islet β-cell dysfunction is a basic pathophysiological characteristic of type 2 diabetes mellitus (T2DM). Appropriate assessment of islet β-cell function is beneficial to better management of T2DM. Protecting islet β-cell function is vital to delay the progress of type 2 diabetes mellitus. Therefore, the Pancreatic Islet β-cell Expert Panel of the Chinese Diabetes Society and Endocrinology Society of Jiangsu Medical Association organized experts to draft the "Clinical expert consensus on the assessment and protection of pancreatic islet β-cell function in type 2 diabetes mellitus." This consensus suggests that β-cell function can be clinically assessed using blood glucose-based methods or methods that combine blood glucose and endogenous insulin or C-peptide levels. Some measures, including weight loss and early and sustained euglycemia control, could effectively protect islet β-cell function, and some newly developed drugs, such as Sodium-glucose cotransporter-2 inhibitor and Glucagon-like peptide-1 receptor agonists, could improve islet β-cell function, independent of glycemic control.
胰岛β细胞功能障碍是2型糖尿病（T2DM）的基本病理生理特征。对胰岛β细胞功能进行恰当评估有助于更好地管理T2DM。保护胰岛β细胞功能对于延缓2型糖尿病的进展至关重要。因此，中华医学会糖尿病学分会和江苏省医学会内分泌学分会胰岛β细胞学组组织专家起草了《2型糖尿病患者胰岛β细胞功能评估与保护的临床专家共识》。该共识指出，可采用基于血糖的方法或结合血糖与内源性胰岛素或C肽水平的方法对β细胞功能进行临床评估。一些措施，包括减重以及早期和持续的血糖正常控制，可有效保护胰岛β细胞功能，一些新研发的药物，如钠-葡萄糖协同转运蛋白2抑制剂和胰高糖素样肽1受体激动剂，可改善胰岛β细胞功能，且独立于血糖控制。
